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Abstract
Background: The therapeutic capacity of human umbilical cord blood mononuclear cells (HUCB-MNC)
and stem cells derived thereof is documented in animal models of focal cerebral ischemia, while
mechanisms behind the reduction of lesion size and the observed improvement of behavioral skills still
remain poorly understood.
Methods: A human in vitro model of neuronal hypoxia was used to address the impact of total HUCB-
MNC (tMNC), a stem cell enriched fraction (CD133+, 97.38% CD133-positive cells) and a stem cell
depleted fraction (CD133-, 0.06% CD133-positive cells) of HUCB-MNC by either direct or indirect co-
cultivation with post-hypoxic neuronal cells (differentiated SH-SY5Y). Over three days, development of
apoptosis and necrosis of neuronal cells, chemotaxis of MNC and production of chemokines (CCL2,
CCL3, CCL5, CXCL8, CXCL9) and growth factors (G-CSF, GM-CSF, VEGF, bFGF) were analyzed using
fluorescence microscopy, FACS and cytometric bead array.
Results: tMNC, CD133+ and surprisingly CD133- reduced neuronal apoptosis in direct co-cultivations
significantly to levels in the range of normoxic controls (7% ± 3%). Untreated post-hypoxic control
cultures showed apoptosis rates of 85% ± 11%. tMNC actively migrated towards injured neuronal cells.
Both co-cultivation types using tMNC or CD133- reduced apoptosis comparably. CD133- produced high
concentrations of CCL3 and neuroprotective G-CSF within indirect co-cultures. Soluble factors produced
by CD133+ cells were not detectable in direct co-cultures.
Conclusion: Our data show that heterogeneous tMNC and even CD133-depleted fractions have the
capability not only to reduce apoptosis in neuronal cells but also to trigger the retaining of neuronal
phenotypes.
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Background
Transplantation of adult stem cells has been shown to be
an auspicious and effective treatment for degenerative and
traumatic neurological diseases [1]. Among degenerative
neurological disorders acute ischemic stroke is the leading
cause of disability and death in industrial nations [2-4].
Acute stroke leads to an increased release of hematopoi-
etic stem and progenitor cells from bone marrow into
peripheral blood [5]. It is assumed that these cells take
part in self-healing processes occurring after neuronal
injury. They are supposed to promote the survival of the
injured brain tissue by producing neurotrophic factors
[6], to enhance endogenous angiogenesis [7] and neuro-
genesis [8] or even to transdifferentiate into neuronal cells
[9]. However, the stroke induced endogenous release of
hematopoietic stem and progenitor cells seems not to be
sufficient to compensate massive loss of brain tissue after
extended ischemic stroke. Therefore, external application
of hematopoietic stem and progenitor cells is expected to
complement current treatment of acute stroke based on
thrombolytic therapy. An appropriate source of hemat-
opoietic stem cells is the mononuclear cell (MNC) frac-
tion of human umbilical cord blood (HUCB) [10-12].
Transplantation of HUCB-MNC as well as enriched HUCB
hematopoietic stem cells into animals which were sub-
jected to focal stroke caused by middle cerebral artery
occlusion (MCAO) ameliorated the animals' functional
outcome and reduced the lesion size [13]. However, there
are still manifold unanswered questions addressing the
beneficial influence of such grafts on injured neuronal
cells.
It has been documented that there is no neuronal transdif-
ferentiation of hematopoietic stem cells in vitro [14-16].
Though so far there is no convincing proof that locally
administered hematopoietic stem cells transdifferentiate
into functionally neuronal cells forming the basis of the
animals' behavioral progression [17].
It has recently been shown that there is no need for MNC
to enter the brain for neuroprotection. Soluble factors like
GDNF, NGF, BDNF or G-CSF are known to promote neu-
roprotection over long-distances [18,19]. This raises many
questions about the cellular mechanisms causing the
functional improvement after grafting [20]. Prevention of
neurons from apoptotic cell death [21] is considered to be
supported by the transplantation and could be directly
connected to improved tissue conservation, lesion size
reduction and superior functional outcome [22].
Cell culture models of neuronal hypoxia complement the
exploration of particular interactions between grafts and
neuronal tissue. Our study is based on a well established
post-hypoxic neuronal cell culture model (SH-SY5Y). This
model was used to address (i) the neuroprotective poten-
tial of stem cell enriched and -depleted HUCB derived cell
fractions, (ii) the impact of these cells especially on apop-
totic status of oxygen-deprived neurons, and (iii) the
mediation of cell-derived survival signals (soluble or cell-
attached).
Results
Direct co-cultivation with each fraction of HUCB-MNC 
reduced apoptosis in post-hypoxic neuronal cells
Hypoxic cultivation (48 hours) of fully matured neuronal
SH-SY5Y cells resulted in an initial rate of apoptosis of
26% ± 13%. Within the following three days rate of apop-
tosis increased to 85% ± 11%. By contrast, normoxic con-
trol cultures showed a stable amount of apoptotic cells
(7% ± 3%) over the whole observation time (data not
shown). Direct co-cultivation with tMNC and CD133-
showed pronounced reduction of neuronal apoptosis.
Similar results were obtained after application of CD133+.
By application of 4.5 × 103 CD133+ they were given in
equal amounts as they exist in tMNC. Though the whole
cell amount of CD133+ was 100 times less then tMNC
administered (Fig. 1A).
Levels of necrosis in post-hypoxic control cultures
remained nearly stable (approximately 25%) over three
days. tMNC and CD133- cell application also induced a
significant reduction of necrosis. CD133+ cells did not
influence the level of necrosis (Fig. 1B).
In indirect co-cultures tMNC and CD133- were also 
sufficient to decrease apoptosis of post-hypoxic neuronal 
cells
Over the entire observation period, direct as well as indi-
rect co-cultivation with tMNC or CD133- exhibited a sig-
nificant reduction of apoptosis. In all co-culture set-ups
percentage of annexin-V positive cells was significantly
lower (p ≤ 0.001) than in post-hypoxic control cultures
(Fig. 2A, B). Direct and indirect co-cultivation of CD133-
resulted in similar rates of apoptosis continuously below
5% of annexin-V positive cells (Fig. 2B). However, still
generating strong neuroprotective effects, the number of
apoptotic neuronal cells in indirect tMNC co-cultures was
significantly higher than in direct co-cultures at Day 2 and
Day 3 (p ≤ 0.001) as shown in figure 2A. Direct co-culti-
vation with tMNC resulted in a stable level of 6% ± 1%
neuronal apoptosis and was therefore significantly lower
than in post-hypoxic control cultures (Day 2: 46% ± 20%;
Day 3: 85% ± 11%).
When tMNC were indirectly co-cultured neuroprotection
was as pronounced as in direct co-cultures on the first day
after hypoxia. Two and three days after application there
was still a significant, but compared to control cultures
reduced, protective effect in the indirect co-cultures whileBMC Neuroscience 2008, 9:91 http://www.biomedcentral.com/1471-2202/9/91
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protection in direct co-cultures was as distinct as on Day 1
(7% ± 8%).
The comparison of both application types using tMNC
and CD133- showed that soluble factors seem to have
strong therapeutic potential (Fig. 2A).
The positive influence of indirect co-cultivation on the
amount of apoptotic cells, revealed by annexin-V detec-
tion, was also confirmed by typical patterns in the cleav-
age of PARP, a late marker of apoptosis (Fig. 3). In indirect
co-cultures with tMNC and CD133- quantities of cleaved
PARP were nearly at the same level on Day 1 post-
hypoxia. On Day 2 and Day 3 neuroprotection by CD133-
resulted in concentrations of cleaved PARP ranging in the
level of the normoxic control (Fig. 3).
Only direct co-cultures of tMNC and CD133- displayed
improved protection from necrosis/late apoptosis as
revealed by Propidium Iodide labeling of post-hypoxic
neuronal cells (Fig. 2C, D). Indirect co-cultivation did not
reduce the percentage of necrotic/late apoptotic neuronal
cells.
tMNC localized in close proximity to post-hypoxic 
neuronal cells
In direct co-cultures many tMNC were found in close spa-
tial relation with post-hypoxic neuronal cells already at
Day 1 (Fig. 4B). This became even more evident at later
time points (Fig. 4D, F). At Day 3, the vast majority of
tMNC was found adjacent to neuronal somata and proc-
esses (Fig. 4F). Interestingly, co-cultivation with tMNC
seemed to have strong positive effects on the preservation
of typical neuronal cell morphology as the formation of
branched processes.
In contrast, in normoxic control cultures tMNC were
evenly spread throughout the culture dish (Fig. 4A, C, E).
Time course of apoptosis and necrosis of post-hypoxic neuronal cells in direct co-cultures with tMNC, CD133+ and CD133- Figure 1
Time course of apoptosis and necrosis of post-hypoxic neuronal cells in direct co-cultures with tMNC, CD133+ 
and CD133-. Box plots showing time course of apoptosis (A) and necrosis/late apoptosis (B) in direct co-cultures of post-
hypoxic neuronal cells with tMNC, CD133- or CD133+ (colored plots). Grey boxes display the development of cell death in 
post-hypoxic neuronal cells directly after hypoxic pre-cultivation of SH-SY5Y cells (Day 0) and 1–3 days post-hypoxia. The 
ordinate represents the percentage of apoptotic and necrotic cells, respectively. Rates of apoptosis and necrosis were calcu-
lated in relation to the total number of SH-SY5Y cells.
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Effects of direct and indirect application of tMNC and CD133- on apoptosis and necrosis of post-hypoxic neuronal cells Figure 2
Effects of direct and indirect application of tMNC and CD133- on apoptosis and necrosis of post-hypoxic neuro-
nal cells. Box plots represent the percentage of annexin-V positive post-hypoxic neuronal cells (A, B) and of PI positive post-
hypoxic neuronal cells (C, D) in direct and indirect co-cultures. Co-cultures were performed with tMNC (A, C) and CD133- 
(B, D). The extents of apoptosis (annexin-V-binding) and necrosis (PI) were analyzed for three days after hypoxia.
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Cytokine secretion patterns induced by direct co-
cultivation with tMNC or CD133- were similar; cytokines 
produced by CD133+ were not detectable
In supernatants of direct co-cultures and corresponding
mono-cultures we assessed concentrations of CCL2,
CCL5, CXCL8, VEGF and bFGF (Fig. 5).
Post-hypoxic neuronal cells secreted the chemokines
CXCL8 and CCL2 and the growth factor VEGF. Low
amounts of CCL5 and bFGF were detectable, as well.
Mono-cultures of tMNC and CD133- displayed similar
growth factor and chemokine secretion patterns: CXCL8
and CCL2 were produced in considerable amounts while
CCL5 and bFGF were secreted at low levels. VEGF was not
present. None of the investigated soluble factors was
detected in supernatants of purified CD133+ mono-cul-
tures.
In direct co-cultures with tMNC or CD133- secretion of
cytokines was regulated very similar: reduction of CXCL8
(p ≤ 0.001) and VEGF (p ≤ 0.001) and increase of CCL5
(Fig. 5). CD133+ co-cultivation only influenced VEGF lev-
els, which decreased significantly (Fig. 5).
Up-regulation of soluble factors in indirect CD133- co-
cultures was associated with long term neuroprotection
In a second set of experiments we investigated different
effects of direct and indirect co-culturing on cytokine
secretion. Therefore, concentrations of CXCL9, CCL3,
VEGF, G-CSF and GM-CSF were measured in normoxic
and post-hypoxic mono-cultures, and co-cultures with
tMNC and CD133-.
Except VEGF neuronal cells did not secret detectable
amounts of either CXCL9, CCL3, G-CSF nor GM-CSF in
mono-cultures. Both, tMNC and CD133- cells expressed
CCL3 and G-CSF but only CD133- produced GM-CSF
(Fig. 6).
In co-cultures with tMNC direct co-cultivation generated
more pronounced effects than indirect co-cultivation, as
seen for the relative up-regulation of CXCL9, GM-CSF
(both, p ≤ 0.05) and CCL3 and the relative down-regula-
tion of VEGF.
Only direct CD133- co-cultivation had an impact on regu-
lation of CCL3, VEGF and GM-CSF. Secretion of all three
cytokines was markedly decreased compared to controls
whereas indirect co-cultivation with CD133- had no effect.
In contrast, the secretion of CXCL9 and G-CSF (p ≤ 0.01)
was markedly induced by indirect co-cultivation with
CD133-. For these cytokines direct co-cultivation showed
no effect (G-CSF) or resulted in a remarkably reduced pro-
duction (CXCL9) as compared to indirect co-cultivation
with CD133- (Fig. 6).
The experiment also revealed the influence of different
HUCB-MNC-derived cell preparations on the cytokine
secretion.
Most prominent, direct co-cultivation with tMNC signifi-
cantly increased expression of CCL3 (p ≤ 0.05) whereas
direct co-cultivation with CD133- resulted in a relative
reduction of this chemokine (p ≤ 0.01).
Discussion
It has been previously shown that HUCB derived MNC as
well as nearly pure stem cell populations obtained from
MNC are able to improve the clinical outcome of animals
after MCAO [23]. In an in vitro model of neuronal hypoxia
we discern cell populations within MNC being able to
improve neuronal survival and disclose potential neuro-
protective mechanisms.
First we studied the effects of tMNC application on the
apoptotic status of post-hypoxic neurons. We found that
direct application of tMNC results in preservation of neu-
ronal morphology based on a constant protection from
apoptosis (Fig. 2A).
For in vivo experiments it has been described that none or
only a minority of systemically administrated cells were
detected in the brain while large quantities were found in
the spleen, in the lungs and in the blood of the animals.
Direct comparison of effects of tMNC and CD133- on late  apoptosis (PARP cleavage) Figure 3
Direct comparison of effects of tMNC and CD133- on 
late apoptosis (PARP cleavage). Bar chart showing con-
centrations of cleaved PARP in lysates of post-hypoxic neu-
ronal cells which were indirectly co-cultivated with tMNC 
(grey shaded bars) or CD133- (black bars). Controls are 
post-hypoxic mono-cultures (grey bars) and normoxic cul-
tures (white bars). Each bar visualizes pooled samples 
obtained from three independent experiments.
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Nevertheless, some studies showed that cell-treatment
improved behavioral deficits [18,23,24]. This indicates
the importance of soluble factors for neuroprotection.
Our data obtained from indirect co-cultures strongly sup-
port this hypothesis. tMNC application was highly protec-
tive, although the anti-apoptotic effect was slightly
weakened after two days (Fig. 2A). Probably, soluble fac-
tors act as "first aid" messengers while longer protection
seems to demand close proximity between tMNC and
neuronal cells. The comparison of direct application of
tMNC to normoxic and post-hypoxic neuronal cells
revealed that only post-hypoxic neuronal cells attracted
tMNC (Fig. 4). The clustering of tMNC around neuronal
cells could explain the enhanced protection from apopto-
sis in direct co-cultures with tMNC at Day 2 and Day 3
(Fig. 4, Fig. 2A). Spatial contiguity is possibly associated
with higher concentrations of neuroprotective mediators
in the micro-environment of injured neuronal cells. Post-
Distribution of tMNC in direct co-cultures Figure 4
Distribution of tMNC in direct co-cultures. Phase contrast fluorescence micrographs of co-cultures of neuronal cells 
(unstained) and tMNC (green). Representative images show post-hypoxic neuronal cultures (B, D, F) in contrast to normoxic 
control cultures (A, C, E) over a time course of three days. Images illustrate the distribution of tMNC in relation to neuronal 
cells. White arrows point at spatial accumulation of tMNC which are clustered around neuronal somata and processes in post-
hypoxic cultures (B, D, F). In normoxic cultures no clustering of tMNC was observed (A, C, E). The black arrow points at a 
conserved neuronal morphology including branched processes. Scale bars indicate 100 μm.
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Cytokine profile in direct co-cultures with tMNC, CD133+and CD133- on Day 3 Figure 5
Cytokine profile in direct co-cultures with tMNC, CD133+and CD133- on Day 3. Control: sum of cytokine concen-
tration from single cultured (grey) post-hypoxic SH-SY5Y cells and HUCB-MNC (light green = tMNC, light red = CD133-, not 
detectable = CD133+). Co-culture: direct co-culture of post-hypoxic SH-SY5Y cells and HUCB-MNC (dark green = tMNC, 
dark red = CD133-, dark yellow = CD133+). Data are derived from four independent experiments and are expressed as pg/ml. 
* significant differences in cytokine concentrations of co-cultures compared to control cultures. Note different axis scaling.
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Effect of co-cultivation system (direct v. indirect) on cytokine secretion during co-cultivation of post-hypoxic neuronal cells  with tMNC and CD133- Figure 6
Effect of co-cultivation system (direct v. indirect) on cytokine secretion during co-cultivation of post-hypoxic 
neuronal cells with tMNC and CD133-. Control: sum of cytokine concentration from single cultured (grey) post-hypoxic 
SH-SY5Y cells and HUCB-MNC (light green = tMNC, light red = CD133-). Co-cultures: co-culture of post-hypoxic SH-SY5Y 
cells and tMNC (direct: dark green, filled; indirect: dark green, striped), co-culture of post-hypoxic SH-SY5Y cells and CD133- 
(direct: dark red, filled; indirect: dark red, striped). Effects are displayed in percent as relative changes to control. Mono-cul-
tures: absolute cytokine concentrations in supernatants of SH-SY5Y normoxic and post-hypoxic mono-cultures (white or grey 
bars, respectively) and tMNC (light green bars) or CD133- (light red bars). * significant changes to control. + significant differ-
ences between co-cultivation systems.
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hypoxic neuronal cells were shown to significantly up-reg-
ulate the adhesion molecule ICAM-1 following hypoxia
[25]. Hence, ICAM-1 (CD54) expression could underlay
the observed co-localization via binding of LFA-1 (CD11)
[26]. Besides adhesion molecules, chemotaxis could
mediate this cellular co-localization. VEGF, known to
exert chemotactic effects on monocytes [27], was pro-
duced by post-hypoxic SH-SY5Y cells (Fig. 6).
To focus the neuroprotective effects of stem cells we
enriched or depleted CD133+ cells from HUCB-MNC.
Purities of 97.38% for the stem cell preparation and a
reduction of CD133+  up to 0.06% for the stem cell
depleted fraction were achieved. In direct co-cultures
CD133+ were applied to neuronal cells in quantities of 4.5
× 103 resembling 1% of the applied tMNC, since CD133+
account for about 1% of total cell number in tMNC prep-
arations. Neuroprotective capacity of nearly pure CD133+
cells was comparable to tMNC (Fig. 1A). According to our
analyses of cytokine production CD133+ cells did not
secrete measureable cytokines neither in mono-cultures
nor in co-cultures with injured neuronal cells (Fig. 5).
Additional experiments using even tenfold elevated num-
bers of stem cells (4.5 × 104) also revealed no detectable
cytokine concentrations and did not result in an increased
neuroprotective capacity (data not shown). Neuroprotec-
tion by the absence of measurable soluble mediators
argues for a stem cell specific therapeutic mechanism
through contiguity. Due to this assumption we did not
include CD133+ in the investigation of indirect co-cul-
tures in this study.
Surprisingly, CD133- cell fractions were also highly suffi-
cient in protection from apoptosis. Therefore, the
observed anti-apoptotic neuroprotective effects of tMNC
in our experiments do not only relay on hematopoietic
stem cell-specific mechanisms. This assumption is sup-
ported by the missing significance in the effect of CD133+
on necrotic/late apoptotic loss of post-hypoxic neuronal
cells (Fig. 1B). tMNC and CD133- significantly reduced
the percentage of PI-positive neuronal cells, whereas
CD133+ did not. Since CD133- in indirect co-cultures were
superior to tMNC in protection from apoptosis and
because of very low amounts of CD133+ in this prepara-
tion, CD133- seem to mediate additional neuroprotective
effects. Possibly, the separation process influenced the
functionality of CD133- cells. FACS analyses of the activa-
tion markers CD25, CD38, CD71 and HLA-DR on tMNC
and on the separated CD133- fraction did not reveal an
increased population of activated cells in our preparations
(data not shown). However, the expression of other acti-
vation molecules cannot be excluded, since this cell pop-
ulation displayed an enhanced secretion of cytokines like
G-CSF, GM-CSF and CCL-3 (Fig. 6). We also cannot rule
out that remaining CD34+ cells could account for the neu-
roprotective activity of the CD133- fraction, since deple-
tion did only reduce the number of CD34+ cells to 77%
(Tab. 1).
The investigation of soluble mediators exhibited that
hypoxia induced a significant increase of VEGF in neuro-
nal cells (Fig. 6, [28]). VEGF is documented to inhibit pro-
apoptotic signaling by Bad (BCL2 antagonist of cell
death), and cleavage of caspase-3, and caspase-9 [29] and
therefore can be claimed as an autocrine self-protection
mechanism of damaged neuronal cells. The neuroprotec-
tive impact of tMNC and CD133-cells in direct applica-
tions was accompanied by prevention of VEGF
production which is typically induced in post-hypoxic
neuronal cells (Fig. 5).
Neuroprotective effects of cell application could be medi-
ated by G-CSF that was found only in mono-cultures of
CD133- but not in mono-cultures of post-hypoxic SH-
SY5Y cells. Schneider et al., 2005 [30] pointed out that
human SH-SY5Y neuroblastoma cells express the G-CSF
receptor and that activation by the neurotrophic G-CSF
reduced NO-induced poly-ADP ribose polymerase
Table 1: Cellular subfractions of MNC
Cellular fractions of Markers Content in tMNC (%) Content in CD133- (%)
I) Myeloid cells CD14+/CD45+ 14.1 ± 4.4 19.5 ± 2.4
II) Lymphocytes (including stem cells) 85.9 ± 4.4 80.5 ± 2.4
Subpopulations of II
B-lymphocytes CD19+/CD45+ 12.3 ± 5.5 14.6 ± 0.5
T-lymphocytes CD3+/CD45+ 73.0 ± 10.2 76.8 ± 1.9
NK-cells CD56+/CD45+ 12.7 ± 4.5 8.3 ± 1.4
Hematopoietic stem/progenitor cells CD133+/CD34+ 1.2 ± 1.0 0.03 ± 0.01
CD133+/CD34- 0.4 ± 0.2 0.03 ± 0.02
CD133-/CD34+ 0.4 ± 0.2 0.34 ± 0.06
Cellular fractions of HUCB-MNC after thawing of cryopreservated cells.
Subpopulations of lymphocytes and stem/progenitor cells are expressed as percent of total lymphocytes.BMC Neuroscience 2008, 9:91 http://www.biomedcentral.com/1471-2202/9/91
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(PARP) and caspase-3 cleavage. Our data support these
observations. At Day 3 in indirect co-cultures supply of G-
CSF by CD133- was associated with cleaved PARP levels in
the range of normoxic cultures (Fig. 3, Fig. 6). G-CSF lev-
els in mono-cultures of tMNC were only slightly above
detection limit and could not provide this anti-apoptotic
effect (Fig. 6).
The decrease of cleaved PARP observed in post-hypoxic
neuronal mono-cultures at Day 3 (Fig. 3) was probably
induced by rising lack of energy due to increased rate of
apoptosis (Fig. 1).
Noticeably, there are application-specific differences in
the regulation of cytokine secretion in co-cultures with
CD133- fractions. Concentrations of CCL3 and G-CSF
were significantly higher in indirect co-cultures than in
direct co-cultures. Possibly these enhanced concentrations
are responsible for a protection from apoptosis in indirect
co-cultures similar to that in direct co-cultures at Day 3.
Indirect co-cultivation with tMNC did not induce
enhanced cytokine levels (Fig. 6) and at the same time did
not exert the same neuroprotective effect on post-hypoxic
SH-SY5Y neurons. This could be explained by spatial
effects: paracrine released cytokines could be more effec-
tive than action of cytokines over a longer distance.
Conclusion
In this study we investigated human umbilical cord blood
derived cell populations (tMNC, CD133+, and CD133-)
according to their ability to protect post-hypoxic neuronal
cells.
For different reasons, as the missing systemic effects and
the disregard of brain cell interactions this in vitro system
does only simplified reflect the action of MNC after
hypoxic brain lesions in vivo. But taken this into account,
our study delivers useful indications for the in vivo appli-
cation of such cells:
So, since purified CD133+ fractions are not superior to
total HUCB-MNC in mediating neuroprotective anti-
apoptotic effects, expensive and time consuming stem cell
separations are not necessarily needed to yield neuropro-
tective cell populations. Furthermore, our study under-
lines the importance of MNC derived soluble factors for
the mediation of neuroprotective effects visible as preven-
tion of neuronal cells from apoptosis. Therefore, future
therapeutic approaches should focus on the sufficient
supply of soluble anti-apoptotic mediators, to reduce
post-hypoxic brain damage.
Methods
Preparation of HUCB samples and isolation of CD133+ 
cells
HUCB samples of healthy full-term neonates were
obtained in accordance with ethical prescripts immedi-
ately after delivery. Samples were processed and analyzed
as described previously [25]. The total MNC (tMNC) frac-
tion gained from Ficoll density gradient (Tab. 1) was
stored in the gaseous phase of liquid nitrogen. Cellular
sub-fractions of tMNC were characterized using CD3-Phy-
coerythrin (PE, Immunotech, Hamburg, Germany),
CD14-Fluorescein isothiocyanate (FITC), CD16+56-PE
(both, Becton-Dickinson, Franklin Lakes, NJ, USA),
CD19-Allophycocyanin (APC) and CD45-FITC, (both,
Beckman Coulter, Krefeld, Germany). Prior to use tMNC
were thawed and stained with carboxy fluoresceindiace-
tate succinimidyl ester (CFSE, Invitrogen, Karlsruhe, Ger-
many).
CD133 positive cells (CD133+) were isolated from
HUCB-MNC using the MACS® immunomagnetic positive
selection protocol (Miltenyi Biotech, Bergisch Gladbach,
Germany). The flow-through fraction was collected as
negative fraction (CD133-) depleted of CD133+. Final
populations were analyzed using a FACSCalibur flow
cytometer equipped with the CellQuest™ software (both
Becton-Dickinson, Franklin Lakes, NJ, USA) and charac-
terized by the use of the following antibodies: CD133/2-
PE, Miltenyi Biotech Bergisch Gladbach, Germany),
CD45-FITC and CD34-APC (both Beckman Coulter,
Krefeld, Germany). Isotype-identical monoclonal anti-
bodies served as controls. CD133+ and CD133- fractions
contained 97.38% and 0.06% CD133 positive cells,
respectively.
Status of activation of tMNC and CD133- was analyzed via
FACS using the antibodies CD25-PE, HLA-DR (Major His-
tocompatibility Complex, class II, cell surface receptor)-
APC (both Becton-Dickinson, Franklin Lakes, NJ, USA),
CD38-PE and CD71-FITC (both Beckman Coulter,
Krefeld, Germany).
Differentiation and hypoxic induction of SH-SY5Y cells
For differentiation 0.9 × 104/cm2  SH-SY5Y cells were
seeded in 16-mm-diameter wells (Greiner Bio-One, Frick-
enhausen, Germany). After 5 days Dulbecco's Modified
Eagle Medium (DMEM)/10 μM all-trans retinoic acid
(Sigma-Aldrich, Steinheim, Germany)/15% fetal calf
serum (PAN-Biotech, Aidenbach, Germany) media was
changed into DMEM-Ham's F12/10 μM RA/5 ng/ml Brain
Derived Neuronal Factor [BDNF, Immunotools Biolance
GmbH, Hanover, Germany]/0.1% Human Serum Albu-
mine [HSA, PAN Biotech GmbH, Aidenbach, Germany]
for another 11 days. Media were exchanged every third
day. Afterwards fully matured neuronal cells were cul-BMC Neuroscience 2008, 9:91 http://www.biomedcentral.com/1471-2202/9/91
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tured under a hypoxic atmosphere (< 1% O2) for 48 hours
[25]. Number of viable cells remained stable between Day
16 and Day 21.
Direct and indirect co-cultivation of post-hypoxic 
neuronal cells with tMNC, CD133+ and CD133- cell 
fractions
Subsequent to hypoxia, direct and indirect co-cultivation
with tMNC, CD133+ or CD133- was carried out under nor-
moxic conditions over a period of three days. Added
tMNC, CD133- (4.5 × 105 cells, both) and CD133+ (4.5 ×
103 cells) were dissolved in 500 μl co-culture medium
(DMEM-Ham's F12, 5 ng/ml BDNF and 0.1% HSA) and
added to differentiated post-hypoxic neuronal SH-SY5Y
cells cultivated in adequate volume of post-hypoxic
medium. Cell ratio of post-hypoxic neuronal cells to
MNC was 1:15 and to CD133+ 1:0.15. For indirect co-cul-
tivation tMNC or CD133- were added in cell impassable
cell culture inserts with a pore size of 0.4 μm (Greiner Bio-
One GmbH, Frickenhausen, Germany).
Prior to co-cultivation with post-hypoxic neuronal cells,
tMNC as well as CD133+ and CD133- were labeled with
CFSE.
Cell viability assay of neuronal cells
Within direct and indirect co-cultures and control cultures
the influence of tMNC, CD133+ and CD133- on neuronal
viability was detected via i) Propidium Iodide (PI, Invitro-
gen, Karlsruhe, Germany) assay for necrosis and late
apoptosis and ii) annexin-V assay (Becton-Dickinson,
Heidelberg, Germany) for apoptosis. The PI- and annexin-
V assays were performed in cell culture plates as described
previously [25]. tMNC, CD133+ and CD133- were distin-
guished from annexin-V-PE or PI positive neuronal cells
by the green CFSE staining.
Cytometric Bead Array for human apoptosis (CBA, Becton
Dickinson, Erembodegem, Belgium) was used to quantify
the apoptosis specific parameter cleaved Poly-ADP-
Ribose-Polymerase I (PARP) in lysates of post-hypoxic
neuronal cells after indirect co-cultivation with tMNC and
CD133-. For cell lyses adherent neuronal cells were rinsed
with PBS and incubated on ice in the supplied buffer for
20 minutes. For analyses pooled samples obtained from
three independent experiments were used.
Cytokine profiling
For cytokine profiling supernatants of direct and indirect
co-cultures were analyzed on Day 3. Supernatants of
tMNC, CD133+ and CD133- mono-cultures and those of
post-hypoxic neuronal cells were also investigated on Day
3. Cytokines were simultaneously measured using CBA
for human soluble proteins (Becton Dickinson, Erembo-
degem, Belgium). Supernatants were screened for the fol-
lowing cytokines: CCL2, CCL3, CCL5, CXCL8, CXCL9
and for the growth factors basic Fibroblast Growth Factor
(bFGF), Granulocyte Colony-Stimulating Factor (G-CSF),
Granulocyte-Macrophage Colony-Stimulating Factor
(GM-CSF) and Vascular Endothelial Growth Factor
(VEGF). The detection limit was 20 pg/ml, except for
CCL2 and VEGF (40 pg/ml).
Statistical analyses of data
Except for apoptosis and necrosis rates all results have
been reported as mean ± SD. Statistical differences were
analyzed by Student's t-test or Mann-Whitney rank sum-
test. P values of ≤ 0.05 were considered statistically signif-
icant (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). Apoptosis
and necrosis rates were logit-transformed to obtain nor-
mally distributed quantities. The effects of time, experi-
mental setting (post-hypoxia), experimental run and the
investigated well were determined univariately, and,
finally multivariately using a mixed-model approach with
time and experimental setting as fixed effects and well and
experimental run as random effects.
Cytokine concentrations of indirect and direct co-cultures
with tMNC, CD133- and CD133+ were compared with the
sum of the concentrations obtained after post-hypoxia of
neuronal cells and corresponding tMNC, CD133+ and
CD133- mono-cultures using a bootstrapping algorithm.
Therefore, we added concentrations which were resam-
pled from e.g. the experiment post-hypoxia and the tMNC
mono-culture and compared the results with concentra-
tions obtained from e.g. the experiment of indirect co-cul-
ture with tMNC. Results were compared with Student's t-
test or Mann-Whitney rank sum test. P-values reported are
based on 10,000 bootstrapping simulations.
Box plots (if applicable) and univariate analyses were
determined using the software package SPSS (SPSS Inc.,
Chicago IL, USA). Mixed Model analyses were performed
using PROC MIXED of the statistical software package SAS
9.1 (SAS Institute Inc., Cary, NC, USA). Bootstrapping
analysis was performed using the statistical software pack-
age "R" [31].
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